Adcentrx Therapeutics

We’re thrilled to announce the first patient dosed in our second clinical program, a Phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 for advanced solid tumors. This milestone reflects our continued commitment to advancing innovative therapies for patients with unmet needs. #HealthcareInnovation #ClinicalTrials #Biotechnology https://lnkd.in/gbmZ7nep

Adcentrx has dosed the first patient in the Phase 1b expansion cohorts of the ADRX-0706 study, our Nectin-4 ADC for advanced solid tumors. With the successful completion of the Phase 1a dose escalation, we’re moving forward in our mission to bring new hope to patients with hard-to-treat cancers. #Biotech #CancerResearch #Healthcare https://lnkd.in/gUK_EmmS

Exciting news! Today we announced FDA clearance of our IND for ADRX-0405, a potential first-in-class ADC targeting STEAP1 for advanced solid tumors. This is the second asset in our pipeline to receive IND clearance, and this milestone brings us closer to our mission of delivering innovative therapies for difficult-to-treat malignancies while continuing to advance our ADC platform. A major step forward for patients battling advanced cancers. #antibodydrugconjugates #innovation #FDA https://lnkd.in/gqePFCQy

Today marks a new chapter for Adcentrx with the formation of our Scientific Advisory Board and the appointment of Mike Varney, Ph.D. and Kerry Blanchard, M.D., Ph.D. as founding members.? ? Dr. Varney and Dr. Blanchard bring extensive expertise in drug discovery and clinical development, providing invaluable insights as we advance our innovative Antibody-Drug Conjugate technology platform and pipeline. Their expertise and guidance will support our efforts to develop groundbreaking therapies for cancer and other life-threatening diseases, reinforcing our commitment to delivering transformative solutions to patients worldwide. ? Please join us in welcoming Dr. Varney and Dr. Blanchard to the Adcentrx team. #biotechnology #healthcare #adc #innovation https://lnkd.in/gsiwVFe9

Today we announced China NMPA clearance of the IND for our lead program, ADRX-0706. This enables us to include China-based clinical centers to broaden geographic representation and accelerate patient enrollment in our ongoing Phase 1a/1b study. #ADC #biotech #NMPA #IND https://lnkd.in/gkMtT-vJ

Attending BIO 2024? Click below to send Adcentrx Therapeutics?a meeting request in the BIO partnering system!?#BIO2024 #ADCs https://lnkd.in/gcVuehSR

We're thrilled to announce that Meng Jiang has joined Adcentrx as Chief Financial Officer! https://lnkd.in/gt86Ehi6

We are pleased to announce that Adcentrx will be presenting preclinical data for the ADRX-0706 Nectin-4 ADC at the AACR Annual Meeting 2024. https://lnkd.in/gmWquTfS